Test Name Results Units Bio. Ref. Interval. Positive

Transcription

1 Lab No Age 35 Years Gender Female 1/9/ AM 1/9/ AM 4/9/ M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE 3 t (1;19) (q23 ;p133); TCF3-BX1(E2A- BX1) (Real Time CR) ositive recursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and 20% in adults Most patients with ALL show an abnormal clone by conventional cytogenetic studiesthe common chromosome translocations in pediatric ALL include t(1;19)(q23;p133); TCF3-BX1(E2A-BX1), t(12;21) (p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement All these translocations are important to detect as they are important prognostic markers Detection of translocation t(1;19) shows improved outcome with intensive chemotherapy Quantifying disease before treatment and after therapy for patients with ALL Assessing residual disease after treatment t (12; 21) (p13;q22); ETV6-RUNX1(TEL-AML1) (Real Time CR) ositive recursor B-cell Acute Lymphoblastic Leukemia (ALL) accounts for 85% Acute leukemias in children and 20% in adults Most patients with ALL show an abnormal clone by conventional cytogenetic studies The common chromosome translocations in pediatric ALL include t(1;19) (q23 ;p133); TCF3-BX1(E2A-BX1), t(12; 21) (p13;q22); ETV6-RUNX1(TEL-AML1) & MLL gene rearrangement All these translocations are important to detect as they are important prognostic markers Detection of translocation t(12;21) which is commonest in B-ALL is associated with good prognosis in children Quantifying disease before treatment and after therapy for patients with ALL Assessing residual disease after treatment BCR-ABL GENE REARRANGEMENT, CR QUALITATIVE (Real Time CR) BCR-ABL gene rearrangement ositive Type of Translocation Major atientreportscsuperanels_general_temlate01_sc (Version 7) age 1 of 8

2 Lab No Age 35 Years Gender Female 1/9/ AM 1/9/ AM 4/9/ M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval Note 1 Sensitivity of the assay is 001% when copies of ABL detected is 100,000 2 Limit of detection is 10 copies of BCR-ABL fusion gene transcripts per CR 3 This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol 4 This test detects Major (M) gene rearrangements namely- e13a2 & e14a2 and Minor (m) gene arrangement e1a2 This test does not detect micro gene rearrangement e19a2 5 Test conducted on Whole blood / Bone Marrow Chronic Myeloid Leukemia (CML) is the commonest myeloproliferative neoplasm and possibly the commonest adult leukemia in India This clonal stem cell disorder is characterized by a proliferation of myeloid cells at all stages of differentiation and the t(922) (q34q11) leading to formation of BCR-ABL fusion gene Cytogenetic and molecular studies are vital for the diagnosis of CML by using detection procedures for hiladelphia chromosome The abnormality is present in over 95% patients of CML while remainder 5% have complex or variant translocations involving additional chromosomes Major gene rearrangements are detected in CML while minor gene rearrangement may be detected in ALL To detect & monitor therapy in CML patients As a prognostic marker in ALL patients resence of BCR-ABL gene rearrangement is associated with poor prognosis ML-RARA GENE REARRANGEMENT, CR QUALITATIVE (Real Time CR) ML - RARA Type bcr 1 ML - RARA Type bcr 2 ML - RARA Type bcr 3 ositive Negative Negative Note 1 Sensitivity of the assay is 001% when copies of ABL detected is 100,000 2 Limit of detection is 10 copies of ML-RARA fusion gene transcripts per CR 3 This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol 4 This test detects 3 types of translocations - bcr 1, bcr 2 & bcr 3 atientreportscsuperanels_general_temlate01_sc (Version 7) age 2 of 8

3 Lab No Age 35 Years Gender Female 1/9/ AM 1/9/ AM 4/9/ M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval 5 Test conducted on Whole blood / Bone Marrow Acute romyelocytic Leukemia (AL) is characterized by a unique reciprocal chromosomal translocation t(15;17) (q22;q11-12) and its underlying fusion gene ML / RARA rearrangement The fusion is seen between romyleocytic (ML) gene on chromosome 15 and RARA gene on chromosome 17 Based on ML breakpoint location, the ML RARA transcripts subtype bcr 1 & bcr 2 (Long transcript type) and bcr 3 (Short transcript type) may be formed For diagnostic identification of ML RARA in cases of Acute romyelocytic Leukemia To assess molecular resistance & predict response to treatments containing ATRA and / or ATO AML ETO GENE REARRANGEMENT t(8;21) (q22;q22);(runx1;runx1t1), CR, QUALITATIVE (Real Time CR) Note ositive 1 Sensitivity of the assay is 001% when copies of ABL detected is 100,000 2 Limit of detection is 10 copies of 8;21 fusion gene transcripts per CR 3 This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol 4 Test conducted on Whole blood / Bone Marrow Cytogenetic aberrations play a central role in the classification of AML These aberrations are detected in 50-70% cases of AML by using standard techniques The AML1(CBFA2, RUNX1)-ETO (MTG8) gene fusion results from the t(8;21)(q22;q22), which is the commonest chromosomal rearrangement associated with AML, being detected in approximately 8% of AML cases in children and young adults Most t(8;21) positive AML s are de novo leukemias - vast majority being M2 FAB subtype This translocation creates chimeric genes encoding fusion proteins that interfere with the function of CBFα and block the maturation of myeloid cells For diagnostic identification of AML having morphological, imuunophenotypic or clinical features strongly suggestive of translocation 8;21 For prognostic evaluation - resence of this translocation is associated with a favorable prognosis atientreportscsuperanels_general_temlate01_sc (Version 7) age 3 of 8

4 Lab No Age 35 Years Gender Female 1/9/ AM 1/9/ AM 4/9/ M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval INV 16 ( p13q22) / t( 16;16)(p13;q22), GENE REARRANGEMENT, CR, QUALITATIVE (Real Time CR) Note ositive 1 Sensitivity of the assay is 001% when copies of ABL detected is 100,000 2 Limit of detection is 10 copies of Inv(16)(p13q22) / t(16;16)(p13;q22) with the CBFB-MYH11 fusion gene transcript per CR 3 This is an in-house developed assay designed as per EAC (Europe Against Cancer) protocol 4 This tests detects A, D, and E transcripts but does not distinguish between them 5 Test conducted on Whole blood / Bone Marrow Cytogenetic aberrations play a central role in the classification of AML These aberrations are detected in 50-70% cases of AML by using standard techniques ericentric inversion of chromosome 16, inv(16) (p13q22), is found in about 4% of cytogenetically abnormal AML cases Inv(16) or the rarer t(16;16)(p13;q22) creates chimeric genes encoding fusion genes that interfere with the function of CBFα and block the maturation of myeloid cells Around 10 different CBFB-MYH11 FG transcripts have been reported More than 85% of positive patients have the type A transcript; type D and E transcripts each represent nearly 5%, whereas all other types occur sporadically For diagnostic identification of AML having morphological, imuunophenotypic or clinical features strongly suggestive of M4eo FAB subtype For prognostic evaluation - resence of this translocation is associated with a favorable prognosis atientreportscsuperanels_general_temlate01_sc (Version 7) age 4 of 8

5 LL LL-ROHINI (NATIONAL REFERENCE SECTOR - 18, BLOCK -E ROHINI Lab No Age 35 Years Gender Female /09/ Ref by Dr UNKNWON Final CHROMOSOME ANALYSIS FOR HEMATOLOGIC MALIGNANCY Specimen Bone marrow Indication To rule out any hematological malignancy Medium RMI , Hi - Karyol RMI Method 24 hr unstimulated cultures with appropriate serum & antibiotics Banding Resolution Banding Technique GTG (G bands by Trypsin and Giemsa) Cytogenetic rofile Metaphases counted 20 Metaphases analysed 20 Metaphases karyotyped 02 Metaphases photographed 02 Karyotype 46,XX[20] Interpretation The analysis of 20 metaphases reveals a normal female karyotype Correlation of chromosomal studies with c linical and hematological findings is recommended Note Karyogram attached Note 1 Metaphases captured by Robotic Microscope 2 Karyogram attached age 5 of 8

6 s LL LL-ROHINI (NATIONAL REFERENCE SECTOR - 18, BLOCK -E ROHINI Lab No Age 35 Years Gender Female /09/ Ref by Dr UNKNWON Final Dr Saurabh Kumar Bhattacharya hd (Cytogenetics) HOD DrVandana Lal MD (athology);ifca Chief of athology Note 1 Metaphases captured by Robotic Microscope 2 Karyogram attached age 6 of 8

7 Lab No Age 35 Years Gender Female 1/9/ AM 1/9/ AM 4/9/ M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval LEUKEMIA DIAGNOSTIC ANEL Acute leukemia-t, B or Myeloid (Flow Cytometry) MARKERS RESULT (%) INTENSITY INTERRETATION T cell markers CD3(cyto) CD5 CD7 B cell markers CD19 CD20 CD22 (cyto) CD79a (cyto) Myeloid markers CD11b CD13 CD15 CD14 CD33 CD36 CD41a CD61 CD64 CD117 MO Glycophorin A Other markers CD10 CD34 CD45 TdT HLA-DR CD Negative Negative 047 Negative Negative 021 Negative Negative 10 Negative Negative 08 Negative Negative 048 Negative Negative 021 Negative Negative 36 Negative Negative 9950 Mod to Bright ositive 756 Dim pos ositive 06 Negative Negative 9803 Bright ositive 017 Negative Negative 021 Negative Negative 010 Negative Negative 8905 Moderate ositive 8775 Dim to Mod ositive 756 Mod to Bright ositive 00 Negative Negative 01 Negative Negative 03 Negative Negative 9924 Dim pos ositive 016 Negative Negative 03 Negative Negative 7625 Dim pos ositive atientreportscsuperanelflowcyto_sc (Version 6) age 7 of 8

8 Lab No Age 35 Years Gender Female 1/9/ AM 1/9/ AM 4/9/ M Ref By Dr UNKNWON Final Test Results Units Bio Ref Interval Type of Specimen Bone Marrow ercent Viability 8598 ercentage cells gated 9127 Gating strategy CD45 vs SSC CBC not received Clinical history? acute leukemia Impression Flow cytometric findings are consistent with acute promyelocytic leukemia (AML) However cytogenetic/molecular studies are essential for final conclusion Correlation with clinical features, peripheral blood findings and bone marrow morphology are recommended DrAtul Thatai hd (Biotechnology) HOD Molecular Diagnostics Dr Biswadip Hazarika MD (athology) Sr Consultant athologist Dr Beena Chandrasekhar hd (Life Sciences) HOD Flowcytometry End of report atientreportscsuperanelflowcyto_sc (Version 6) age 8 of 8